Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Effectiveness of Recombinant Follicle-Stimulating Hormone Treatment in Patients With Oligo-Asthenospermia at Different Levels of Dna Fragmentation Index: A Phase Ii Clinical Trial Publisher



Soltani S1 ; Tafazoli N2, 3 ; Emadzadeh M4 ; Aghaee A5 ; Ebrahiminia Milani SE6 ; Seyedi Vostakolaee SM2 ; Rezayat AA7
Authors
Show Affiliations
Authors Affiliations
  1. 1. Kidney Transplantation Complications Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
  2. 2. Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
  3. 3. Pediatric Urology and Regenerative Medicine Research Center, Gene, Cell and Tissue Research Institute, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran
  4. 4. Clinical Research Development Unit, Ghaem Hospital, Mashhad University of Medical Sciences, Mashhad, Iran
  5. 5. Nuclear Medicine Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
  6. 6. Department of Anesthesia and Intensive Care, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
  7. 7. Department of Urology, Ghaem Hospital, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

Source: Current Urology Published:2025


Abstract

Objective: This study aimed to perform an evaluation of changes in spermogram parameters after follicle-stimulating hormone (FSH) therapy in infertile males having oligo-asthenospermia at different levels of DNA fragmentation index (DFI). Materials and methods: Infertile men with oligo-asthenospermia, no underlying urogenital disease (such as varicocele), and medically fertile partners were enrolled over 1 year. Semen parameters, FSH, luteinizing hormone, and testosterone levels were determined; also, a Sperm DNA Fragmentation Assay Kit (Hamun Teb Pishro, Tehran, Iran) was used for determining sperm DFI at baseline. Participants were categorized into 3 groups based on DFI: DFI <15% (group 1), DFI of 15%–30% (group 2), and DFI >30% (group 3). All participants received subcutaneous recombinant FSH (150 mg every other day) for 6 months. Sperm specimens were tested 6 months after intervention (a single sperm control test). Results: Sixty males whose average age was 28.4 years were enrolled. Only group 3 (poor fertility) exhibited a significant rise in sperm concentration (p = 0.001) and motility (p < 0.05) after FSH treatment. Group 1 (DFI <15%) and group 2 (DFI of 15%–30%) showed increased mean sperm concentration and motility postintervention, although these alterations were not significantly different. Follicle-stimulating hormone levels increased significantly in all 3 groups after FSH administration. Serum luteinizing hormone and testosterone levels were not significantly increased in any of the groups. Conclusions: Follicle-stimulating hormone treatment improves sperm concentration and motility in men with oligo-asthenospermia, with significant improvements observed in men with DFI >30%. DNA fragmentation index can be a predictive indicator of response to FSH treatment in such patients. Copyright © 2024 The Authors.
Related Docs
1. Controversy and Consensus on the Management of Elevated Sperm Dna Fragmentation in Male Infertility: A Global Survey, Current Guidelines, and Expert Recommendations, World Journal of Men's Health (2023)
2. The Effect of Body Mass Index on Sperm Dna Fragmentation: A Systematic Review and Meta-Analysis, International Journal of Obesity (2020)
3. Comparison of Embryological Results of Microinjection in Two Groups of Men With and Without Requesting Sperm Dna Fragmentation Index Measurement, BioMed Research International (2024)
4. Correlation of Sperm Dna Fragmentation Index With Semen Parameters, Lifestyle and Clinical Pregnancy Outcome After Intracytoplasmic Injection, Journal of Family and Reproductive Health (2024)
5. The Knowledge Domain and Emerging Trends in the Infertility Field: A 67-Year Retrospective Study, Health Care for Women International (2024)
6. Assessing the Potential of Hspa2 and Adam2 As Two Biomarkers for Human Sperm Selection, Human Fertility (2020)
Experts (# of related papers)
View all Related Experts
Hamed Akhavizadegan (2)
Hojjat Zeraati (1)